Literature DB >> 11210093

Technetium-99m MIBI single photon emission computed tomography as an indicator of prognosis for patients with lung cancer-preliminaly report.

T Komori1, I Narabayashi, R Matsui, K Sueyoshi, T Aratani, K Utsunomiya.   

Abstract

PURPOSE: We performed technetium-99m hexakis-2-methoxyisobutylisonitrile (Tc-99m MIBI) single photon emission computed tomography (SPECT) in 23 patients with primary lung cancer between July 1993 and March 1996. We evaluated the relationships among the uptake ratio, retention index and the prognosis after radiation therapy and/or chemotherapy.
MATERIALS AND METHODS: Tc-99m MIBI SPECT was performed at 30 minutes and at 3 hours after intravenous injection of 600 MBq of Tc-99m MIBI with three gamma camera detectors (GCA-9300A/HG) on transverse SPECT images. Regions of interest were set in the area of abnormal uptake of Tc-99m MIBI and in the contralateral normal lung. The ratio of uptake in the lesion to that in the contralateral normal lung was obtained on early images (early ratio; ER) as well as delayed images (delayed ratio: DR). The retention index (RI) was calculated as follows: RI = (DR - ER)/ER x 100. The ratio was compared with survival time and prognostic factors.
RESULTS: There was no correlation between ER and DR. The patients with high RI survived longer than those with low RI (median survival, 19.4 months vs. 9.4 months; p = 0.0104 by the Mantel-Cox test).
CONCLUSION: These results suggest that RI is the most useful among Tc-99m MIBI indices of primary lung cancer in predicting prognosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11210093     DOI: 10.1007/bf02988286

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  3 in total

Review 1.  ABC transporters: unvalidated therapeutic targets in cancer and the CNS.

Authors:  Robert W Robey; Paul R Massey; Laleh Amiri-Kordestani; Susan E Bates
Journal:  Anticancer Agents Med Chem       Date:  2010-10-01       Impact factor: 2.505

Review 2.  Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies.

Authors:  Laleh Amiri-Kordestani; Agnes Basseville; Karen Kurdziel; Antonio Tito Fojo; Susan E Bates
Journal:  Drug Resist Updat       Date:  2012-03-29       Impact factor: 18.500

3.  A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.

Authors:  Ronan J Kelly; Deborah Draper; Clara C Chen; Robert W Robey; William D Figg; Richard L Piekarz; Xiaohong Chen; Erin R Gardner; Frank M Balis; Aradhana M Venkatesan; Seth M Steinberg; Tito Fojo; Susan E Bates
Journal:  Clin Cancer Res       Date:  2010-11-16       Impact factor: 12.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.